After Ozempic: the next-gen weight-loss drugs coming next

Why there's an "after Ozempic" at all

Semaglutide, sold as Ozempic and Wegovy, is a single GLP-1 agonist. It was the first drug to make double-digit weight loss look routine, and it opened the whole category. Almost everything behind it in the pipeline does one of three things it doesn't: adds a second hormone signal (GIP, glucagon, or amylin), stacks a third, or moves the drug out of a weekly shot and into a daily pill.

That's the real story of "next-gen." Not a better version of the same thing. A different receptor combination, or a different delivery, aimed at more loss or fewer needles.

Here is what people actually mean when they search this, with the furthest clinical stage each compound has reached as of August 2026 and the strongest weight-loss result it has reported. One of them is no longer pipeline at all: the first small-molecule GLP-1 pill was approved in April 2026. Read the caution under the table before you rank anything by the biggest number.

The catch: these numbers are not head-to-head

The single most misleading thing you can do with the table above is line the percentages up and crown a winner. They come from different trials, different lengths, different doses, and different phases. A Phase 2 number at 13 weeks and a Phase 3 number at 80 weeks are not the same measurement.

Three rules keep you honest:

• Length changes what you see. A 13-week result and an 80-week result are not the same measurement and cannot be lined up. That does not license you to project the short one forward either: weight loss can keep going, plateau, or reverse when people stop, and nobody knows which until the long trial runs.
• Early-phase numbers are provisional. Phase 2 figures come from smaller, shorter, more controlled trials. The average can move up or down once a drug reaches a large, long Phase 3, so treat any pre-Phase-3 number as a first read, not the final one.
• The same trial reports more than one number. A drug's loss depends on which analysis you cite (everyone assigned to it versus only those who stuck with it) and which dose. That's why a single compound shows up as a range.

So the table tells you what stage each compound has reached and roughly what it can do. It does not tell you which is strongest. Only a head-to-head trial does that, and most of these have never been tested against each other.

The triple agonist: Retatrutide

Retatrutide is the one drawing the most attention, because it hits three receptors at once (GLP-1, GIP, and glucagon) and its Phase 3 loss held up. In the TRIUMPH-1 trial it reached roughly 25 to 28 percent at 80 weeks depending on how the data is analyzed. The 30 percent number people quote comes from somewhere narrower: a prespecified extension that enrolled 532 participants who had a baseline BMI of 35 or higher and had completed 80 weeks on their assigned dose. Those on 12 mg reached 30.3 percent at 104 weeks. It is a real result from a selected group at a longer timepoint, not the trial average.

Two more Phase 3 readouts landed on July 23, 2026. TRIUMPH-2, in adults with obesity or overweight plus type 2 diabetes, reported up to about 20.8 percent weight loss at 80 weeks along with A1c reduction. TRIUMPH-3, in adults with severe obesity and established cardiovascular disease, reported up to about 22.6 percent at 80 weeks. Both are lower than the TRIUMPH-1 headline. Before reading that as fading, note that these are different populations: people with type 2 diabetes have consistently lost less weight on incretin drugs across every program that has tested both, and TRIUMPH-3 enrolled a heavier group with established heart disease. Separate trials cannot prove why the numbers differ, but comparing them as if they measured the same thing is the error to avoid.

On timing, Lilly has said it is completing the manufacturing data package and plans to submit for US approval in the first quarter of 2027. If you have read an older article promising a 2026 filing, that guidance has moved. Nothing is approved, and nothing sold today is approved retatrutide. Full profile: Retatrutide.

The amylin route: CagriSema and Amycretin

These two attack appetite through a different pathway, amylin, on top of GLP-1.

CagriSema is the combination approach: semaglutide and cagrilintide dosed together in one weekly shot. Its pivotal Phase 3 trials are done and it is under FDA review, so it could be one of the first amylin-based options to actually land.

Amycretin, which Novo has since renamed zenagamtide, is the same idea built into a single molecule instead of a combination, and it comes in both an injectable and an oral form. It moved into Phase 3 in early 2026, which puts any approval years out, but it is the one to watch if the single-molecule bet pays off.

The dual agonists still in trials: VK2735 and Survodutide

VK2735 is a GLP-1 and GIP dual agonist, the same broad mechanism as tirzepatide, with both a weekly injectable and a once-daily oral tablet in development. The injectable is in Phase 3; the oral form is heading there. It is the compound the "needle-free" crowd tracks most closely.

Survodutide pairs GLP-1 with glucagon, a combination intended to act on energy expenditure and liver metabolism alongside appetite. Its Phase 3 SYNCHRONIZE-1 trial reported 13.0% loss at 76 weeks on the primary analysis (against 5.4% on placebo) and 16.6% on the analysis that measures people who stayed on treatment. The higher number is the one that travels; both are real, and they answer different questions. It also carries a breakthrough-therapy designation for MASH (fatty liver disease), so its story is as much about the liver as the scale.

Already approved, just not here: Mazdutide

Mazdutide is a GLP-1 and glucagon dual agonist already approved in China for weight management, based on Phase 3 data. It is not FDA approved and is not lawfully marketed in the US. It matters because it shows the dual GLP-1/glucagon mechanism clearing a real regulator, not just a trial.

The other shift: pills, not just shots

Most of the drugs above are weekly shots. The change a lot of needle-averse people care about is oral delivery, and that door is no longer "coming." It is open.

Oral semaglutide has been around for years, as a diabetes pill since 2019 and then approved for weight management in late 2025. It is a peptide in a tablet, which is why it comes with the swallowing rules: empty stomach, small sip of water, wait before eating.

The bigger change is orforglipron, approved by the FDA on April 1, 2026 under the brand name Foundayo, for adults with obesity or with overweight plus a weight-related condition. It is not a peptide at all. It is a small molecule that happens to hit the same GLP-1 receptor, which is why it can be taken at any time of day with no food or water restrictions. In the ATTAIN-1 trial it produced average weight loss of roughly 7.5 to 11.2 percent at 72 weeks depending on dose, against about 2.1 percent on placebo. That sits below the injectable dual and triple agonists. It is not automatically the strongest pill either: oral semaglutide reported larger loss in its own trials, and the two have not been compared head to head.

It carries the same GLP-1 class cautions: gastrointestinal side effects are the common ones, and the label carries the class boxed warning for thyroid C-cell tumors, so it is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2. Details: Orforglipron.

Oral VK2735 and oral zenagamtide are still in trials behind it. Whether an oral version gives up ground to its injectable sibling is an open question rather than a rule, and the trials that exist do not answer it: VK2735's injectable and oral results come from separate studies, and oral semaglutide was tested against placebo, not against the shot. Nobody has run the head-to-head that would settle it.

Bottom line

The pattern behind "after Ozempic" is simple: more receptors, or a pill instead of a needle. The pill half already happened. Oral semaglutide got its weight-management approval in late 2025, and the first small-molecule GLP-1 pill, orforglipron, followed in April 2026. On the receptor half, CagriSema is under FDA review and retatrutide is the next big filing, planned for the first quarter of 2027. Amycretin, VK2735, and survodutide are further out but each carries a distinct angle (single-molecule amylin, oral dual-agonist, liver disease). Mazdutide is approved, but in China.

None of this is a buy signal. Some of what is named here can be prescribed in the US today, orforglipron and oral semaglutide among them, and mazdutide is legitimately sold in China. The rest are investigational, and for an investigational drug there is no ordinary commercial route at all. Access outside a clinical trial exists only through narrow authorized pathways such as expanded access, and those run through a physician and the sponsor, not a website. A vial sold outside any of that is not the trial drug in any verifiable sense, whatever the label says. Educational only, not medical advice.

Go deeper:

• Compare any two of these head to head, the real per-pair verdicts
• The full peptide index, stage, evidence tier, and status for every compound
• The Honest Peptide Report Card, hype versus evidence across the most-searched peptides